Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 20,508

Document Document Title
WO/2019/008152A1
The present invention provides novel compounds of formula (I) that are useful as inhibitors of the PD-l/PD-Ll protein/protein interaction. The compounds may be used in the treatment of cancer, infectious diseases and neurodegenerative di...  
WO/2019/007821A1
The invention relates to 4,6-dihalogen-dibenzothiophene and 4,6-dihalogen-dibenzofuran-3-thioether derivatives of formula (I), in which W, X, R1, R2, A1, Z1 and n are defined as cited in claim 1, to their production, their use as compone...  
WO/2019/002173A1
The present invention relates to a compound of formula (I): wherein the meanings for the various substituents are as disclosed in the description, having dual pharmacological activity towards both the α2δ subunit, in particular the α2...  
WO/2019/004614A1
The present invention provides a novel heterocyclic compound and an organic light emitting element using same.  
WO/2018/235926A1
The purpose of the present invention is to provide an α, β-unsaturated amide compound or a pharmaceutically acceptable salt thereof or the like, which has anti-cancer activity or the like. An α, β-unsaturated amide compound represent...  
WO/2018/231635A1
The present disclosure relates to novel δ-opioid receptor agonists, and the method of making and using the novel δ-opioid receptor agonists. The novel δ-opioid receptor agonists are selective δ-opioid receptor agonists that have subs...  
WO/2018/231015A1
The present specification relates to an anthracene derivative represented by chemical formula 1 and an organic light-emitting device comprising same.  
WO/2018/232298A1
The present invention provides a compound having the structure: and use of the compound for inhibiting the growth of or killing a fungus  
WO/2018/228968A1
The invention relates to compounds of formula (I), in which present groups and parameters have the meanings cited in claim 1, to their preparation, to their use as components in liquid-crystalline media and to electro-optical display ele...  
WO/2018/232358A1
Visibly transparent photovoltaic devices are disclosed, such as those are transparent to visible light but absorb near-infrared light and/or ultraviolet light. The photovoltaic devices make use of transparent electrodes and near-infrared...  
WO/2018/225018A1
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates...  
WO/2018/217439A1
The present invention relates to novel substituted [5,6]cyclic-4(3H)-pyrimidinone compounds of formula (I) and their preparation methods. (I) In particular, the present invention relates to novel substituted [5,6]cyclic-4(3H)- pyrimidino...  
WO/2018/213150A1
The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mi...  
WO/2018/210631A1
The present invention refers to a process for a Rh-catalyzed Anti-Markovnikov hydrocyanation of terminal alkynes which process discloses, for the first time, the highly stereo- and regio-selective hydrocyanation of terminal alkynes to fu...  
WO/2018/198975A1
Provided is a light-emitting element having excellent luminance life. Disclosed is a light-emitting element comprising a positive electrode, a negative electrode, a first organic layer provided between the positive electrode and the nega...  
WO/2018/198973A1
Provided is a composition that is useful for producing a light-emitting element having excellent external quantum efficiency. Disclosed is a composition comprising at least two types of compounds represented by formula (C-1), and a phosp...  
WO/2018/198971A1
Provided is a composition useful for manufacturing a light-emitting element having excellent light-emitting efficiency. A composition containing a phosphorescent compound represented by formula (1) and a compound represented by formula (...  
WO/2018/199466A1
The present invention provides a novel compound and an organic light-emitting element including same.  
WO/2018/199797A1
The invention relates to the chemistry of organic compounds, pharmacology and medicine, and concerns the prevention and/or treatment of hyperproliferative diseases associated with the malignant transformation of cells expressing the enzy...  
WO/2018/198974A1
Provided is a light-emitting element having excellent luminance life. This light-emitting element comprises: a positive electrode; a negative electrode; and a first organic layer and a second organic layer provided between the positive e...  
WO/2018/198972A1
Provided is a composition useful for manufacturing a light-emitting element having excellent luminance life. The composition comprises a compound represented by formula (C-1), a metal complex represented by formula (1), and a metal compl...  
WO/2018/189060A1
The invention comprises novel chiral metal complex compounds of the formula (I) wherein M, PR2, R3 and R4 are outlined in the description, its stereoisomers, in the form as a neutral complex or a complex cation with a suitable counter io...  
WO/2018/190516A1
The present invention provides a novel heterocyclic compound and an organic light-emitting element utilizing same.  
WO/2018/188795A1
The present invention relates to sulfonamide-, sulfinamide- or sulfonimidamide containing compounds which bind to the liver X receptor (LXRa and/or LXRß) and act preferably as inverse agonists of LXR.  
WO/2018/181054A1
Provided are: an organic semiconductor element in which an organic semiconductor layer comprises a compound represented by formula (1) and/or a compound represented by formula (2), or a polymer having either of the structures represented...  
WO/2018/177151A1
Compounds such as vidofludimus and its analogues useful in modulating the activity of nuclear receptor FXR. Also disclosed are the methods for treating FXR-mediated disease or process in a mammal, comprising administering to the mammal a...  
WO/2018/183411A1
Compounds of formula (I) as inhibitors of DCNl and compositions containing the same are disclosed. Methods of using the DCNl inhibitors in the treatment of diseases and conditions wherein inhibition of DCNl provides a benefit, like oxida...  
WO/2018/172852A1
The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and co...  
WO/2018/172423A1
The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p¸ q, L, ׇ, X and m are as defined herein. The compound...  
WO/2018/174293A1
An organic electroluminescence element comprising, in the stated order, an anode, an organic layer, a light-emitting layer, and a cathode, the organic layer including the compound represented in formula (20), and the light-emitting layer...  
WO/2018/173058A1
The present invention provides processes for the preparation of diverse heterocyclic scaffolds from alpha-enaminone building bloc of formula (I).  
WO/2018/169261A1
The present invention provides: a compound capable of enabling high luminous efficiency, a low driving voltage, and an improved lifespan of an element; an organic electric element using the same; and an electronic device thereof.  
WO/2018/168714A1
Provided is an oxime ester compound represented by general formula (Iα) or (Iβ). (In the formulae: R1 to R6 and R101 to R108 each independently denote a group represented by general formula (II), a hydrogen atom, a halogen atom, a nitr...  
WO/2018/170067A1
Provided herein are compositions comprising a compound of Formulas I, II, or III, and compositions a compound comprising a moiety of Formula IV, which are useful for sensitizing and/or activating pro-apoptotic activity of BAX. Methods of...  
WO/2018/164265A1
A compound represented by formula (1) provides an organic electroluminescent element that exhibits exceptional luminous efficiency. (In formula (1), R1-R8, R11-R18, R21, R22, L1, L2, L3, Ar1, and Ar2 are as defined in the description.)  
WO/2018/164545A1
The present invention provides a novel compound and an organic light emitting element using the same.  
WO/2018/160022A1
The present disclosure relates to an organic electroluminescent device. The organic electroluminescent device of the present disclosure comprises a specific combination of a light-emitting layer and an electron transport zone, thereby pr...  
WO/2018/157842A1
The present invention provides a use of 2-(substituted phenylamino)benzoic acid FTO inhibitor in treating leukemia.  
WO/2018/158256A2
The present invention discloses novel compounds which are useful as potassium channel openers, in particular as openers of the Kv7.4 potassium channel. The novel compounds are compounds according to formula (I), wherein - n = 0 or 1, - R...  
WO/2018/157843A1
The preparation method provides 2-(substituted benzene matrix) aromatic formate FTO inhibitor, a preparation method therefor, and applications thereof. Specifically, disclosed in the present invention are a 2-(substituted benzene matrix)...  
WO/2018/157801A1
The present invention relates to a cyano group-substituted fused bicyclic derivative, and a pharmaceutical composition comprising the compound. The compound or the pharmaceutical composition can be used for inhibiting xanthine oxidase an...  
WO/2018/159970A1
The present disclosure relates to an organic electroluminescent device comprising a light-emitting layer and a hole transport zone. By comprising a specific combination of a light-emitting layer and a hole transport zone, it is possible ...  
WO/2018/159650A1
The purpose of the present invention is to provide a compound which has a guanidine skeleton and inhibits the protease activity of MALT1 to exhibit a therapeutic effect or prophylactic effect on autoimmune diseases such as psoriasis. The...  
WO/2018/158256A3
The present invention discloses novel compounds which are useful as potassium channel openers, in particular as openers of the Kv7.4 potassium channel. The novel compounds are compounds according to formula (I), wherein - n = 0 or 1, - R...  
WO/2018/157981A1
The present invention relates to triarylamine compounds of general formula (I). The present invention further relates to methods for producing said compounds, oligomers, polymers or dendrimers and to formulations containing said compound...  
WO/2018/156046A1
The invention relates to the field of chemical engineering of organic and heteroorganic compounds. The invention also relates to new donor-acceptor oligomers of a general formula (I), where n represents a whole number from 1 to 4 and m r...  
WO/2018/151861A1
Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, pr...  
WO/2018/149850A1
The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic...  
WO/2018/149856A1
The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as tocompositions and ophthalmic ...  
WO/2018/149853A1
The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic...  

Matches 1 - 50 out of 20,508